Related Experiment Video
Updated: May 6, 2026
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
Angiotensin converting enzyme inhibition in asymptomatic left ventricular systolic dysfunction and early heart
1Department of Medicine, New England Medical Center, Boston, Massachusetts 02111, USA.
Insights
Angiotensin converting enzyme (ACE) inhibitors benefit patients with reduced left ventricular systolic function, even without heart failure symptoms. These drugs help prevent heart failure progression, hospitalizations, and reduce mortality in asymptomatic individuals.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Reduced left ventricular (LV) systolic function is a precursor to heart failure.
- Heart failure poses a significant and growing public health challenge.
Purpose of the Study:
- To evaluate the benefits of ACE inhibitors in patients with asymptomatic LV systolic dysfunction.
- To determine if ACE inhibitors can prevent adverse cardiac events and heart failure development.
Main Methods:
- The study reviewed existing clinical data and trials involving ACE inhibitor use.
- Analysis focused on outcomes in patients with asymptomatic LV systolic dysfunction.
Main Results:
- ACE inhibitors prevent adverse ventricular remodeling, delaying heart failure onset.
- Treatment reduces heart failure hospitalizations and mortality rates in this population.
- A decrease in myocardial infarction incidence was observed, though mechanisms are unclear.
Conclusions:
- ACE inhibitors offer substantial benefits for patients with asymptomatic LV systolic dysfunction.
- Preventing the progression of LV dysfunction is a key mechanism of benefit.
- Early ACE inhibitor treatment is crucial for managing heart failure risk.
Abstract:
Benefit achieved through use of angiotensin converting enzyme (ACE) inhibitors in patients with reduced left ventricular (LV) systolic function is not confined to those with clinical manifestations of heart failure. Although rates of adverse clinical events are lower in asymptomatic patients, within this population ACE inhibitors have been shown to prevent adverse ventricular remodelling, prevent the development of clinical heart failure, reduce rates of hospitalization for heart failure and, in some studies, reduce mortality. Most of the benefit derived appears to be associated with preventing the progression of LV hypertrophy, dilatation, and dysfunction, resulting in prevention of heart failure. Additionally, the incidence of myocardial infarction is decreased, although the exact physiological basis for this benefit remains uncertain. Given the enormity and growth of heart failure as a public health problem and the potential for influencing the underlying pathophysiology, ACE inhibitor treatment offers substantial benefit for patients with asymptomatic LV systolic dysfunction.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
01:17Pathophysiology of Heart Failure
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:29Heart Failure II: Pathophysiology
01:30Heart Failure IV: Classification and Diagnostic Evaluation
01:30Heart Failure V: Medical Management